Effects of fedotozine on gastric emptying and upper gastrointestinal symptoms in diabetic gastroparesis.
BACKGROUND
Delayed gastric emptying and upper gastrointestinal symptoms occur frequently in patients with diabetes mellitus.


OBJECTIVE
To evaluate the effects of fedotozine on gastric emptying and gastrointestinal symptoms in diabetic gastroparesis.


METHODS
Thirty-one diabetic patients (20 type 1, 11 type 2) with gastroparesis were randomized to receive fedotozine (30 mg as the tartrate) or placebo t.d.s. Measurements of gastric emptying (100 g ground beef labelled with 20 MBq 99mTc-sulphur colloid chicken liver and 150 mL 10% dextrose labelled with 10 MBq 113mIn-DTPA) and gastrointestinal symptoms were performed before and after 12-16 days of treatment. Data are the mean +/- s.d.


RESULTS
Of the 31 patients enrolled, two were excluded from analysis. Data from the remaining 29 patients (18 type 1, 11 type 2; 22 female, seven male), aged 42.7 +/- 11.1 years (of whom 14 were randomized to fedotozine and 15 to placebo), were analysed. Fedotozine had no effect on either gastric emptying (solid retention at 100 min; fedotozine: baseline, 84 +/- 15%; treatment, 73 +/- 23% vs. placebo: baseline, 83 +/- 10%; treatment, 70 +/- 20%) or liquid 50% emptying time (fedotozine: baseline, 59 +/- 32 min; treatment, 58 +/- 38 min vs. placebo: baseline, 44 +/- 9 min; treatment, 43 +/- 21 min) or gastrointestinal symptoms (fedotozine: baseline, 4.4 +/- 2.9; treatment, 4.1 +/- 3.9 vs. placebo: baseline, 4.9 +/- 4.2; treatment, 4.8 +/- 3.9).


CONCLUSIONS
Fedotozine has no effect on gastric emptying in patients with diabetic gastroparesis.
Jones
K L
KL
Department of Medicine, University of Adelaide, Royal Adelaide Hospital, SA, Australia. kjones@medicine.adelaide.edu.au
Wishart
J M
JM
Berry
M K
MK
Abitbol
J L
JL
Horowitz
M
M
D000328:Adult; D000855:Anorexia / Q000188:drug therapy / Q000209:etiology; D001593:Benzyl Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D048909:Diabetes Complications; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D018589:Gastroparesis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006356:Heartburn / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008297:Male; D017063:Outcome Assessment, Health Care; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use*
D001593:Benzyl Compounds; D001786:Blood Glucose; D011437:Propylamines; C067749:fedotozine